Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Dec;24(18):921-930.
doi: 10.2217/pgs-2023-0191. Epub 2023 Dec 6.

Pharmacogenomic knowledge and awareness among diverse patients treated with angiotensin converting enzyme inhibitors

Hetanshi Naik  1 , Michelle Y O'Connor  2 , Saskia C Sanderson  1 , Nancy Pinnell  1 , Mingshu Dong  1 , Amy Wiegand  1 , Aniwaa Owusu Obeng  3   4   5 , Noura S Abul-Husn  6 , Stuart A Scott  1
Affiliations

Pharmacogenomic knowledge and awareness among diverse patients treated with angiotensin converting enzyme inhibitors

Hetanshi Naik et al. Pharmacogenomics. 2023 Dec.

Abstract

We developed novel electronic phenotyping algorithms for the BioMe biobank data, which accurately identified angiotensin converting enzyme inhibitor (ACEi)-induced angioedema cases and controls. A survey was mailed to all 1075 patients and 91 were returned. Over a third reported that prescribing physicians had not discussed with them the concepts of interindividual drug response variability or adverse event risk, and 73% of patients were previously unaware of pharmacogenomics; however, most patients were interested in having pharmacogenomic testing. Moreover, 67% of patients indicated that pharmacogenomic testing would positively influence their medication compliance. In addition to identifying an innovative approach to define biobank cohorts for pharmacogenomic studies, these results indicate that patients are interested in pharmacogenomic testing, which could translate to improved adherence.

Keywords: adverse events; angioedema; angiotensin converting enzyme inhibitors; biobanks; electronic health records; pharmacogenomics.

PubMed Disclaimer

Conflict of interest statement

Competing interests disclosure

NS Abul-Husn is an employee and equity holder of 23 and Me and serves as a scientific advisory board member for Allelica. The authors have no other competing interests or relevant affiliations with any organization or entity with the subject matter or materials discussed in the manuscript apart from those disclosed.

Figures

Figure 1.
Figure 1.. Algorithm to select Angiotensin converting enzyme inhibitors-induced angioedema cases and controls.
Inclusion and exclusion criteria used to select cases and controls are illustrated. Cases differed from controls by age (61 vs 58 years; p < 0.01), gender (67 vs 49% female; p < 0.01) and self-reported race (62 vs 27% African–American; p < 0.01), consistent with known risk factors for ACEi-induced angioedema. ACEi: Angiotensin converting enzyme inhibitors.
Figure 2.
Figure 2.. Assessment of participants knowledge of pharmacogenomics.
The level of agreement to knowledge questions is shown on a 5-point Likert scale from ‘strongly disagree’ to ‘strongly agree’.
Figure 3.
Figure 3.. Level of worry regarding scenarios involving pharmacogenomic testing.
Participant level of worry about specific scenarios is shown on a 4-point Likert scale from ‘not at all worried’ to ‘very worried’.
Figure 4.
Figure 4.. Participants views on concerns, benefits and preferences on pharmacogenomic testing.
The level of agreement to questions assessing these items is shown on a 5-point Likert scale from ‘strongly disagree’ to ‘strongly agree’.
See this image and copyright information in PMC

References

    1. Messerli FH, Nussberger J. Vasopeptidase inhibition and angio-oedema. Lancet 356(9230), 608–609 (2000). - PubMed
    1. Brown NJ, Ray WA, Snowden M, Griffin MR. Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema. Clin. Pharmacol. Ther. 60(1), 8–13 (1996). - PubMed
    1. Vleeming W, van Amsterdam JG, Stricker BH, de Wildt DJ. ACE inhibitor-induced angioedema. Incidence, prevention and management. Drug Saf. 18(3), 171–188 (1998). - PubMed
    1. Duan QL, Nikpoor B, Dube MP et al. A variant in XPNPEP2 is associated with angioedema induced by angiotensin I-converting enzyme inhibitors. Am. J. Hum. Genet. 77(4), 617–626 (2005). - PMC - PubMed
    1. Scott SA, Nicoletti P. Novel Pharmacogenomic Locus Implicated in Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema. J. Am. Coll. Cardiol. 78(7), 710–712 (2021). - PubMed

MeSH terms

Substances

LinkOut - more resources